Semprus BioSciences Corp. appointed former Boston Scientific Corp. (NYSE:BSX) design engineer Douglas Weaver for a new executive role.
The Cambridge, Mass.-based firm named Weaver group leader of process development. He will head the company’s development of manufacturing processes and help the company scale up its vascular access products, Semprus said.
The role is similar to Weaver’s former position at Boston Scientific, where he was "principal design assurance engineer," with BSX’s endoscopy division, according to his LinkedIn profile. Before to his work at BSX, Weaver held senior development posts at Genzyme Biosurgery Inc. (NSDQ:GENZ) and Focal Inc., a synthetic surgical sealant manufacturer that Genzyme acquired, according to Semprus.
"Doug’s expertise in design control and process development combined with his ability to lead highly skilled teams across multiple facilities make him the perfect fit for Semprus BioSciences," Semprus CEO David Lucchino said in prepared remarks.
The company is developing coatings for medical devices called Sustain Performance, which feature the first non-leaching single surface modification that simultaneously reduces bacterial growth and blood clots from devices, according to a press release.
Semprus tapped vice president of business development Donald Anderson and VP of product development Laurence Roth in February and added pharma vet Colin Gardner and MIT professor Michael Cima to its advisory board in March.
